Flash e-reader

 Go to e-reader chapter








Table 9.7a

Patients and Annual Death Rates Per 1,000 Patient-Years at Risk, 2000 to 2008

Rates for Recipients during First Year after Deceased Donor Liver Transplantation

Primary Diagnosis Year of Transplant
2000 2001 2002 2003 2004 2005 2006 2007 2008
Total Patients 4,384 4,451 4,692 5,040 5,449 5,667 5,835 5,625 5,567
Deaths 675 703 672 754 753 840 795 650 692
Rate 174.7 178.5 159.3 167.3 153.0 165.1 149.8 125.6 135.4
Non-Cholestatic Cirrhosis Patients 2,865 2,873 2,929 2,975 3,294 3,411 3,438 3,309 3,128
Deaths 436 448 422 460 442 480 472 397 390
Rate 172.0 175.2 159.7 172.5 147.5 155.2 150.5 130.5 135.5
Cholestatic Liver Disease/Cirrhosis Patients 467 462 476 500 492 448 516 520 421
Deaths 44 54 43 62 62 51 51 36 45
Rate 102.0 128.2 96.4 137.4 138.2 123.5 106.6 73.0 115.6
Acute Hepatic Necrosis Patients 415 350 352 340 407 441 353 344 311
Deaths 82 69 85 68 70 83 50 44 43
Rate 233.7 231.6 297.9 237.4 200.0 220.9 157.6 143.1 153.8
Biliary Atresia Patients 155 170 163 173 182 175 143 175 177
Deaths 17 24 20 13 14 11 18 8 20
Rate 121.3 161.0 134.5 80.6 82.3 66.3 140.2 47.6 125.1
Metabolic Diseases Patients 154 159 141 176 168 184 204 151 174
Deaths 16 18 12 18 23 26 31 16 16
Rate 113.9 124.2 91.9 110.3 153.8 157.7 174.0 115.2 98.4
Malignant Neoplasms Patients 82 139 327 365 483 642 823 825 1,066
Deaths 19 23 42 49 76 100 110 98 122
Rate 273.2 190.0 140.3 146.4 175.4 173.3 144.8 128.6 122.7
Other Patients 246 298 304 511 423 366 358 301 290
Deaths 61 67 48 84 66 89 63 51 56
Rate 309.8 271.9 179.2 189.1 176.1 299.9 203.0 195.3 225.2


Source: OPTN/SRTR Data as of October 1, 2010.

(-) = None in category.

(*) = For cohorts with fewer than 10 patients, rates are imprecise and are not reported.

Multi-organ transplants are excluded.

Includes patients transplanted during the year and having reported data one-year after transplant.

Time at risk covers the period from transplant date until the date of death or one-year anniversary of the transplant.

See Technical Notes for further details.